[go: up one dir, main page]

MX2010001484A - Derivados de pirrolidin-2-ona como moduladores del receptor de androgeno. - Google Patents

Derivados de pirrolidin-2-ona como moduladores del receptor de androgeno.

Info

Publication number
MX2010001484A
MX2010001484A MX2010001484A MX2010001484A MX2010001484A MX 2010001484 A MX2010001484 A MX 2010001484A MX 2010001484 A MX2010001484 A MX 2010001484A MX 2010001484 A MX2010001484 A MX 2010001484A MX 2010001484 A MX2010001484 A MX 2010001484A
Authority
MX
Mexico
Prior art keywords
androgen receptor
pyrrolidin
derivatives
receptor modulator
salt
Prior art date
Application number
MX2010001484A
Other languages
English (en)
Inventor
Atsushi Hasuoka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MX2010001484A publication Critical patent/MX2010001484A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un compuesto representado por la fórmula (I) de acuerdo con la reivindicación 1 o una sal de él, que tiene una acción moduladora superior del receptor de andrógeno.
MX2010001484A 2007-08-07 2008-08-06 Derivados de pirrolidin-2-ona como moduladores del receptor de androgeno. MX2010001484A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007205966 2007-08-07
JP2007299658 2007-11-19
PCT/JP2008/064500 WO2009020234A2 (en) 2007-08-07 2008-08-06 Pyrrolidin-2 -one derivatives as androgen receptor modulator

Publications (1)

Publication Number Publication Date
MX2010001484A true MX2010001484A (es) 2010-03-04

Family

ID=40329363

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001484A MX2010001484A (es) 2007-08-07 2008-08-06 Derivados de pirrolidin-2-ona como moduladores del receptor de androgeno.

Country Status (34)

Country Link
US (2) US8420694B2 (es)
EP (1) EP2176220B1 (es)
JP (1) JP5292390B2 (es)
KR (1) KR20100049644A (es)
CN (1) CN101821235B (es)
AR (1) AR067823A1 (es)
AU (1) AU2008284662B2 (es)
BR (1) BRPI0814957B8 (es)
CA (1) CA2695852C (es)
CL (1) CL2008002313A1 (es)
CO (1) CO6160326A2 (es)
CR (1) CR11266A (es)
CY (1) CY1114067T1 (es)
DK (1) DK2176220T3 (es)
DO (1) DOP2010000053A (es)
EA (1) EA017429B1 (es)
ES (1) ES2406685T3 (es)
GE (1) GEP20125571B (es)
HR (1) HRP20130374T1 (es)
JO (1) JO2864B1 (es)
MA (1) MA31639B1 (es)
ME (1) ME01579B (es)
MX (1) MX2010001484A (es)
MY (1) MY159910A (es)
NZ (1) NZ583624A (es)
PE (1) PE20090899A1 (es)
PL (1) PL2176220T3 (es)
PT (1) PT2176220E (es)
RS (1) RS52812B (es)
SI (1) SI2176220T1 (es)
TN (1) TN2010000062A1 (es)
TW (1) TWI418543B (es)
WO (1) WO2009020234A2 (es)
ZA (1) ZA201001289B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009020234A2 (en) * 2007-08-07 2009-02-12 Takeda Pharmaceutical Company Limited Pyrrolidin-2 -one derivatives as androgen receptor modulator
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
US8067448B2 (en) 2008-02-22 2011-11-29 Radius Health, Inc. Selective androgen receptor modulators
PE20091653A1 (es) * 2008-03-26 2009-11-14 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso
WO2011097496A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
MX342898B (es) 2010-05-12 2016-10-18 Radius Health Inc * Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
ES2550319T3 (es) * 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
WO2013152170A1 (en) * 2012-04-04 2013-10-10 Catylix, Inc. Selective androgen receptor modulators
EP3378472A1 (en) 2012-08-09 2018-09-26 Dynamis Therapeutics, Inc. Combinations of meglumine
KR102069008B1 (ko) 2012-09-21 2020-02-11 메르크 파텐트 게엠베하 C-c 삼중 결합을 갖는 화합물 및 액정 혼합물에서 이의 용도
SI3122426T1 (sl) 2014-03-28 2023-04-28 Duke University Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
KR101597327B1 (ko) * 2014-04-24 2016-02-24 동아에스티 주식회사 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
CN103951688B (zh) * 2014-05-06 2016-04-20 成都安斯利生物医药有限公司 一种制备3,5-二氟-4-甲基苯硼酸的方法
CA3027563C (en) 2016-06-22 2024-07-02 Ellipses Pharma Ltd AR+ METHODS FOR BREAST CANCER TREATMENT
ES2981967T3 (es) 2017-01-05 2024-10-14 Radius Pharmaceuticals Inc Formas polimórficas de RAD1901-2HCl
WO2020010216A1 (en) 2018-07-04 2020-01-09 Radius Pharmaceuticals, Inc. Polymorphic forms of rad 1901-2hcl
PE20211733A1 (es) 2019-01-11 2021-09-06 Gruenenthal Chemie Amidas de pirrolidina sustituidas
PH12021551950A1 (en) 2019-02-12 2022-05-23 Radius Pharmaceuticals Inc Processes and compounds
CN110204505B (zh) * 2019-05-31 2023-02-03 荆门医药工业技术研究院 (s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺
US20230012570A1 (en) * 2019-11-20 2023-01-19 Medshine Discovery Inc. Bicyclic compound used as selective androgen receptor modulator

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4141399A1 (de) 1991-12-16 1993-06-17 Bayer Ag 4-(substituierte)amino-3-arylpyrrolinon-derivate
JP3390744B2 (ja) * 1998-09-22 2003-03-31 山之内製薬株式会社 シアノフェニル誘導体
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
FR2817472B1 (fr) 2000-12-06 2003-01-03 Oreal Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
HRP20040588A2 (en) 2001-12-06 2004-10-31 Gtx Inc Treating muscle wasting with selective androgen receptor modulators
JP4316232B2 (ja) 2001-12-28 2009-08-19 武田薬品工業株式会社 アンドロゲン受容体拮抗剤
WO2003057669A1 (fr) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Antagonistes du recepteur androgene
CN100537520C (zh) 2002-06-17 2009-09-09 田纳西大学研究基金会 N-桥连选择性雄激素受体调节剂及其使用方法
NZ538713A (en) * 2002-08-12 2007-01-26 Takeda Chemical Industries Ltd Fused benzene derivative and use
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EP1747193A1 (en) * 2004-05-11 2007-01-31 Pfizer Products Incorporated Benzonitrile derivatives to treat musculoskeletal frailty
ZA200610270B (en) 2004-05-17 2008-06-25 Acadia Pharm Inc Androgen receptor modulators and method of treating disease using the same
ATE552235T1 (de) 2004-06-07 2012-04-15 Univ Tennessee Res Foundation Selektive androgen-rezeptor-modulator und anwendungsverfahren dafür
EP1836202B1 (en) 2005-01-10 2016-12-21 Acadia Pharmaceuticals Inc. Aminophenyl derivatives as selective androgen receptor modulators
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
US7807691B2 (en) 2005-05-13 2010-10-05 Eli Lilly And Company Substituted N-arylpyrrolidines as selective androgen receptor modulators
JP5070054B2 (ja) 2005-08-01 2012-11-07 武田薬品工業株式会社 環状アミン化合物
US20090042857A1 (en) * 2006-02-20 2009-02-12 Masuo Yamaoka Novel Pharmaceutical
MX2009000715A (es) * 2006-07-19 2009-07-22 Osurf Ohio State University Re Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos.
RU2009106214A (ru) * 2006-07-26 2010-09-10 Новартис АГ (CH) Ингибиторы ундекапренилпирофосфатсинтазы
JP5241507B2 (ja) 2006-11-30 2013-07-17 武田薬品工業株式会社 環状アミン化合物
WO2009020234A2 (en) * 2007-08-07 2009-02-12 Takeda Pharmaceutical Company Limited Pyrrolidin-2 -one derivatives as androgen receptor modulator

Also Published As

Publication number Publication date
BRPI0814957A2 (pt) 2015-02-03
CL2008002313A1 (es) 2009-05-15
TN2010000062A1 (en) 2011-09-26
CR11266A (es) 2010-03-22
US8420694B2 (en) 2013-04-16
AU2008284662B2 (en) 2013-07-25
KR20100049644A (ko) 2010-05-12
WO2009020234A3 (en) 2009-04-16
PL2176220T3 (pl) 2013-08-30
RS52812B (sr) 2013-10-31
US20110098336A1 (en) 2011-04-28
PT2176220E (pt) 2013-04-09
CN101821235A (zh) 2010-09-01
GEP20125571B (en) 2012-07-10
JP5292390B2 (ja) 2013-09-18
DOP2010000053A (es) 2010-07-15
CY1114067T1 (el) 2016-07-27
CA2695852A1 (en) 2009-02-12
US7834051B2 (en) 2010-11-16
PE20090899A1 (es) 2009-08-06
ZA201001289B (en) 2011-04-28
EA201070246A1 (ru) 2010-08-30
TW200916439A (en) 2009-04-16
CO6160326A2 (es) 2010-05-20
JP2010535704A (ja) 2010-11-25
CN101821235B (zh) 2012-11-14
MA31639B1 (fr) 2010-08-02
EA017429B1 (ru) 2012-12-28
ME01579B (me) 2014-09-20
MY159910A (en) 2017-02-15
BRPI0814957B1 (pt) 2019-12-03
AU2008284662A1 (en) 2009-02-12
JO2864B1 (en) 2015-03-15
DK2176220T3 (da) 2013-06-10
WO2009020234A2 (en) 2009-02-12
ES2406685T3 (es) 2013-06-07
BRPI0814957B8 (pt) 2021-05-25
EP2176220B1 (en) 2013-03-27
SI2176220T1 (sl) 2013-05-31
HRP20130374T1 (en) 2013-05-31
HK1143972A1 (en) 2011-01-21
CA2695852C (en) 2017-01-03
US20090042967A1 (en) 2009-02-12
EP2176220A2 (en) 2010-04-21
NZ583624A (en) 2012-06-29
AR067823A1 (es) 2009-10-21
TWI418543B (zh) 2013-12-11

Similar Documents

Publication Publication Date Title
TN2010000062A1 (en) Pyrrolidin -2-one derivatives as androgen receptor modulator
TN2011000286A1 (en) Spiroheterocyclic n-oxypiperidines as pesticides
EA201071201A1 (ru) ИНДОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ НИКОТИНОВОГО РЕЦЕПТОРА АЦЕТИЛХОЛИНА ПОДТИПА α-71
TN2012000575A1 (en) Compositions and methods for modulating the wnt signaling pathway
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
HRP20120323T1 (en) Diarylhydantoin compounds
DK201100432A (en) New use
TW200744588A (en) Pharmaceutical composition for external use
WO2007005887A3 (en) Androgen receptor modulator compounds, compositions and uses thereof
UA94833C2 (en) Substituted bicyclolactams
GEP20125426B (en) Tricyclic compounds and their use as glucocorticoid receptor modulators
MX343625B (es) Composiciones plagicidas.
MY152114A (en) Novel pyrazole-4-n-alkoxycarboxamides as microbiocides
IN2012DN02876A (es)
TW200800956A (en) 2-Aminopyrimidine derivatives
MX2009008921A (es) Derivados de tiazole en la forma de moduladores de receptores acoplados por proteina g.
TN2010000064A1 (en) Novel herbicides
MX2012003389A (es) Moduladores de gpr40 de pirrolidina.
UA103625C2 (en) 5-hetrocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enons as herbicides
MX2010001364A (es) Derivados de ciclopentandiona puenteados triciclicos como herbicidas.
GB201305247D0 (en) Amide Compounds
PH12015501146A1 (en) Hydantoin derivative
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
TN2010000094A1 (en) Novel herbicides
MX2011008126A (es) Compuestos de indol sustituidos como moduladores del receptor 1 de bradiquinina.

Legal Events

Date Code Title Description
FG Grant or registration